Loading
Normunity develops antibody medicines that direct the immune system's T cells against tumours. Its lead, NRM-823, recognises a target found on several solid tumours but not on normal tissue, and is in an early trial.
Normunity, located in Boston, Massachusetts, and New Haven, Connecticut, creates anti-cancer therapies at the interface of the immune system and the tumour, built on research by scientific founder Lieping Chen at Yale School of Medicine; Rachel Humphrey was founding chief executive. It announced a USD 65 million Series A in October 2022, led by Canaan with Sanofi Ventures, Taiho Ventures and Osage University Partners, and a USD 75 million Series B in January 2025, co-led by Samsara BioCapital and Enavate Sciences with Regeneron Ventures, Pfizer Ventures and YK Bioventures. Its lead, NRM-823, is a first-in-class T cell engager against what the company describes as a novel, highly tumour-specific target absent in normal systemic tissues; the first patient was dosed in November 2025 in a phase 1a/1b study (NCT07182149) alone and with checkpoint inhibition in head and neck, oesophageal, gastric and gastro-oesophageal junction cancers. Its first registered cancer trial, NCT07182149, was posted on ClinicalTrials.gov in September 2025.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series B · Co-led by Samsara BioCapital and Enavate Sciences. | 2025 | $75M | normunity.com |
| Series A · Led by Canaan, with Sanofi Ventures, Taiho Ventures and Osage University Partners. | 2022 | $65M | normunity.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares Pfizer Ventures, Head and neck squamous cell carcinoma.
Shares Oesophageal squamous cell carcinoma, Oesophageal and junctional adenocarcinoma.
Shares Oesophageal squamous cell carcinoma, Oesophageal and junctional adenocarcinoma.
Shares Samsara BioCapital, Bispecific antibodies, Head and neck squamous cell carcinoma.
Shares Oesophageal squamous cell carcinoma, Oesophageal and junctional adenocarcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/